Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences

Open Access

Peer-reviewed

Research Article

Antoni Sicras-Mainar ,

* E-mail: asicras@bsa.cat

Affiliation Directorate of Planning, Badalona Serveis Assistencials, S.A., Badalona, Barcelona, Spain
⨯
Pablo Guijarro,

Affiliation Pfizer, Madrid, Spain
⨯
Beatriz Armada,

Affiliation Pfizer, Madrid, Spain
⨯
Milagrosa Blanca-Tamayo,

Affiliation Department of Psychiatry, Badalona Serveis Assistencials, S.A., Badalona, Barcelona, Spain
⨯
Ruth Navarro-Artieda

Affiliation Medical Documentation, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
⨯

Reader Comments (0)

Drug metabolism
Is the Subject Area "Drug metabolism" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Antidepressants
Is the Subject Area "Antidepressants" applicable to this article?

Thanks for your feedback.
Antidepressant drug therapy
Is the Subject Area "Antidepressant drug therapy" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Primary care
Is the Subject Area "Primary care" applicable to this article?

Thanks for your feedback.
Depression
Is the Subject Area "Depression" applicable to this article?

Thanks for your feedback.
Mental health therapies
Is the Subject Area "Mental health therapies" applicable to this article?

Thanks for your feedback.